---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-000776"
form_type: "8-K"
ticker: "BLFS"
cik: "0000834365"
company_name: "BIOLIFE SOLUTIONS INC"
filed_at: "2024-01-08T23:59:59+00:00"
generated_at: "2026-06-07T02:45:27.843886+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# BioLife Q4 preliminary revenue $32.7M, down 26% YoY; cell processing up 11% sequentially

## Summary
- Q4 2023 total preliminary unaudited revenue $32.7M, down 26% vs Q4 2022 ($44.3M).
- Cell processing platform revenue $14.8M, down 27% YoY but up 11% sequentially from Q3 2023.
- Full-year 2023 revenue $143.3M, down 11% from $161.8M in 2022.
- Divestiture of freezer business progressing; expected to close in Q1 2024.
- CEO cites 14 approved CGT therapies using BioLife products; 10 more potential by year-end.

## SEC filing metadata
- accession: 0001628280-24-000776
- form_type: 8-K
- ticker: BLFS
- cik: 0000834365
- company_name: BIOLIFE SOLUTIONS INC
- filed_at: 2024-01-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/834365/000162828024000776/0001628280-24-000776-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/834365/000162828024000776/blfs-20240108.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-000776
- JSON: https://secwatch.observer/filing/0001628280-24-000776.json
- Plain text: https://secwatch.observer/filing/0001628280-24-000776.txt

## Key facts
- Earnings Releases
  BIOLIFE SOLUTIONS INC reported the fourth quarter of 2023 results: revenue $32.7 million.
  - Period: the fourth quarter of 2023
  - Revenue: $32.7 million
  - Result: preliminary results
  source text: Preliminary and unaudited revenue for the fourth quarter of 2023 was $32.7 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/834365/000162828024000776/0001628280-24-000776-index.htm
- Earnings Releases
  BIOLIFE SOLUTIONS INC reported the full year 2023 results: revenue $143.3 million.
  - Period: the full year 2023
  - Revenue: $143.3 million
  - Result: preliminary results
  source text: Preliminary and unaudited revenue for the full year 2023 was $143.3 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/834365/000162828024000776/0001628280-24-000776-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.